Search the Newsreel

MFS Blended Research International Equity Fund's GSK PLC(LSE:GSK) Holding History

MFS Blended Research International Equity Fund holds 1.57 million shares of GSK PLC (LSE:GSK), valued at £39.86 million, representing 0.85% of their portfolio. The fund acquired these shares at an average price of £20.07, and based on the current price of £18.57, has an …

Senior GSK plc (GSK) leaders acquire Ordinary Shares through Share Reward Plan

Several senior leaders and one closely associated person at GSK plc acquired Ordinary Shares under the company's Share Reward Plan on August 11, 2026. The acquisitions were made on the London Stock Exchange at a price of £19.3496 per share, with most individuals acquiring …

GSK plc (GSK) president reports acquisition of notional ADS in savings plan

GSK plc reported that its President, Maya Martinez-Davis, acquired 9.016 notional American Depositary Shares (ADS) at $52.9600 per ADS on August 7, 2026. This transaction occurred on the New York Stock Exchange and was part of her GSK Executive Supplemental Savings Plan account. The …

GSK Plc (GSK) Stock Analysis: Exploring A 9.66% Potential Upside In The Healthcare Giant

GSK Plc (GSK) shows a potential upside of 9.66% with a market capitalization of $106.07 billion and a forward P/E of 10.31, suggesting potential undervaluation. The company exhibits strong financial health with 5.30% revenue growth, a 33.38% ROE, and a 3.43% dividend yield. Analysts …

GSK plc (GSK) Aktuelle Aktien-News

Noticias de acciones de GSK plc (GSK)

Análise e Previsão das Ações da GSK plc (GSK)

Glaxosmithkline plc - ADR (GSK) News, Articles, Events & Latest Updates

This article provides recent news and updates concerning Glaxosmithkline plc (GSK), alongside other pharmaceutical companies. Key highlights include GSK beating Q2 earnings and revenue estimates and announcing a cost-saving plan, as well as news about Moderna's mRNA flu vaccine approval and other companies' financial …

GSK plc (GSK) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

GSK plc (GSK) reports 4,045,411,246 voting rights as of July 2026

GSK plc has reported its total voting rights as 4,045,411,246 as of July 31, 2026, in accordance with the Financial Conduct Authority's disclosure requirements. The company's issued share capital included 4,316,292,310 Ordinary Shares, with 270,881,064 of these held in Treasury, which do not carry …

GSK India first-quarter profit rises on steady vaccine demand

GlaxoSmithKline Pharmaceuticals (GSK India) reported a 15.7% increase in first-quarter profit, driven by stable demand for its vaccine and drug portfolio. The company's revenue from operations rose by 16.6%, and it plans to launch new treatments, including Blenrep for multiple myeloma and the Arexvy …

GSK (LSE:GSK) Opens Cambridge Research Hub And Teams Up With Relation Therapeutics

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. GSK (LSE:GSK) plans to establish a new global R&D centre on the Cambridge Biomedical …

Price to earnings forward of GSK plc – LSE:GSK

This article focuses on the "Price to earnings forward" metric for GSK plc, listed on the London Stock Exchange under the ticker GSK. It appears to be a financial data snippet from a larger platform like TradingView, providing specific financial information without extensive commentary …

GSK PLC (GSK) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Accelerated Pipeline ...

This article first appeared on GuruFocus. Revenue: Q2 sales up 5% to more than GBP8.4 billion. Core Operating Profit: Grew 7%. Core Earnings Per Share (EPS): Up 9%. Cash Generation: Positive at GBP4.3 billion. Q2 Dividend: 17p. Gross Margin: Improved 250 basis points due …

Why GSK Plc (GSK) Stock Is Up Today

This article explains why GSK Plc's stock is experiencing an increase today. It details the specific factors and news items contributing to the positive movement in GSK's share price.

GSK: Healthy Results, But Limited Stock Upside (Rating Downgrade) (NYSE:GSK)

GSK reported healthy Q2 and H1 2026 results with core turnover and EPS growth at the upper end of guidance. However, the stock’s forward P/E and dividend yield offer limited upside, leading to a rating downgrade. Despite maintaining a long-term sales target, the projected …

GSK plots £400m Cambridge research hub in push for cancer breakthrough

GSK plans to acquire a new 300,000 sq ft site on the Cambridge Biomedical Campus - GSK GlaxoSmithKline (GSK) will invest £400m in a major new science hub in Cambridge as part of plans to pour more money into developing new cancer drugs. The …

New survey reveals Canadians underestimate chronic hepatitis B and its link to liver cancer

Nearly 9 in 10 Canadians have little to no awareness of chronic hepatitis B (CHB) Only 31% rank CHB as a high cancer risk, revealing a significant gap between perception and reality Just 14% report to have been tested for CHB, yet CHB causes …

GSK plc 2026 Q2 - Results - Earnings Call Presentation (NYSE:GSK) 2026-07-28

GSK admits 70,759 shares to trading on London Stock Exchange

GSK plc announced the admission of 70,759 ordinary shares to trading on the London Stock Exchange's Main Market. These shares, part of the GlaxoSmithKline plc Share Save Plan 2022, bring the total number of GSK ordinary shares admitted to trading to 4,316,292,310. The newly …

GSK plc (GSK) adds 70,759 Share Save Plan shares to London listing

GSK plc has announced the admission of 70,759 new ordinary shares to trading on the London Stock Exchange Main Market. These shares are part of the GlaxoSmithKline plc Share Save Plan 2022 and are fully fungible with existing shares. Following this admission, the total …

GSK (LSE:GSK) Could Be 10% Undervalued On Jideytro FDA Approval

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. GSK (LSE:GSK) has just received US FDA approval for Jideytro, a ROS1 selective inhibitor for previously treated ROS1 positive non small cell lung …

GSK (LSE:GSK) Stock Still Looks Undervalued As Jideytro Wins FDA Approval

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. GSK (LSE:GSK) has just received US FDA approval for Jideytro, a ROS1 selective inhibitor for previously treated ROS1 positive non small cell lung …

GSK (LSE:GSK) Wins FDA Nod For Jideytro As Bexsero And Jemperli Advance

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. GSK (LSE:GSK) received US FDA approval for Jideytro (zidesamtinib) for previously treated ROS1-positive non-small …

GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC

GSK plc GSK announced that the FDA has approved Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer (NSCLC). Jideytro was added as a late-stage candidate to GSK's oncology portfolio through the recently closed acquisition of Nuvalent. Jideytro is a next-generation, highly selective …

GSK: Glaxosmithkline plc - ADR Latest Stock Price, Analysis, News and Trading Ideas

This page provides the latest stock price, analysis, news, and trading ideas for Glaxosmithkline plc (GSK) ADR. It includes current market data, financial fundamentals such as market cap, PE ratio, and EPS, and recent news headlines related to GSK's drug approvals and developments. The …

GSK (GSK) Q4 2024 earnings summary

GSK announced strong Q4 2024 results with 8% sales growth to over GBP 31.4 billion, driven by specialty medicines and vaccines. Core operating profit increased by 13%, and core EPS rose by 12% to 159.3p, leading to a dividend increase and a new GBP …

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease1 Next-generation design aims to address key efficacy and tolerability challenges of treating ROS1-positive NSCLC GSK's first approval in lung cancer, part of a growing …

GSK (NYSE: GSK) gains early FDA approval for ROS1 lung cancer therapy

GSK has received early FDA approval for Jideytro (zidesamtinib), a therapy for ROS1-positive non-small cell lung cancer in adult patients who have previously used a ROS1 kinase inhibitor. This approval, based on the ARROS-1 trial showing a 44% objective response rate, comes ahead of …

By mid-2027, analysts expect £6,000 in GSK shares to be worth…

Analysts predict that a £6,000 investment in GSK (LSE: GSK) shares could grow to over £6,700 within 12 months, and nearly £6,900 with dividends. Despite recent stagnation and some setbacks like the halt of a key drug development, the company's low valuation and the …

GSK Unveils New Data on Long-Acting HIV Treatments Ahead of AIDS Conference

GSK PLC (NYSE: GSK) announced new data from its subsidiary ViiV Healthcare regarding long-acting HIV treatments, to be presented at the 26th International AIDS Conference. The studies include findings on two-drug and long-acting injectable regimens, aiming to advance HIV treatment options. GSK's current P/E …

GSK plc Stock (GSK) Closed Down by 3.17% on Jul 20: Facts Behind the Movement

GSK plc (GSK) stock fell by 3.17% on July 20, driven by renewed concerns over the Zantac litigation, heightened competition in vaccine markets, rising R&D costs, and broader regulatory scrutiny in the healthcare sector. Technical indicators suggest potential selling pressure, while analysts have adjusted …

EMA reviews GSK (NYSE: GSK) plan for 1-dose Bexsero meningitis B booster

GSK has announced that the European Medicines Agency (EMA) has accepted its submission to update the label for Bexsero to include a single-dose booster for individuals aged 10 years and older who were previously vaccinated. This proposed booster aims to help reduce the burden …